Sage Therapeutics price target lowered to $8.50 by TD Cowen

TD Cowen lowered its price target on Sage Therapeutics to $8.50 from $9.00, maintaining a Hold rating, following Supernus Pharmaceuticals' acquisition offer at $8.50 per share; the firm does not expect competing bids. The acquisition, valued at up to $795 million, includes potential contingent value rights, and is expected to close in Q3 2025 with minimal regulatory hurdles. Despite a Q1 2025 net loss of $62.2 million (EPS of -1.01) and revenue of $14.06 million, TD Cowen remains confident in the long-term potential of Sage’s postpartum depression treatment, Zurzuvae.

Analysis

Sage Therapeutics (SAGE) is set to be acquired by Supernus Pharmaceuticals (SUPN) for $8.50 per share in cash, with potential additional value from contingent value rights (CVRs) that could bring the total to $12 per share, valuing the deal up to $795 million. This transaction, anticipated to close in Q3 2025 with minimal regulatory hurdles, has led to analyst adjustments: TD Cowen revised its SAGE price target to $8.50, maintaining a Hold rating and expressing doubt about a superior competing offer, while Truist Securities increased its target to $9.00 and Piper Sandler downgraded SAGE to Neutral with an $8.50 target. SAGE's stock, currently trading at $9.1 after a significant 72% gain over six months and a 30% rise in the past week, is now considered technically overbought according to InvestingPro analysis. This M&A activity follows Sage's Q1 2025 financial report, which revealed a net loss of $62.2 million (EPS of -1.01, missing the -0.99 forecast) and revenue of $14.06 million (below the $14.14 million expectation). For Supernus, the acquisition is strategically aimed at incorporating Zurzuvae, Sage’s key postpartum depression treatment, into its portfolio and achieving up to $200 million in annual cost synergies. Sage Therapeutics also projects its product XERZUVEY will reach cash flow positivity by the end of 2026.

Key Decisions for Investors

• Sage Therapeutics investors should weigh the $8.50 per share cash offer plus the potential, albeit uncertain, value of contingent value rights against the current market price of $9.1, considering the stock's technically overbought status and analyst skepticism regarding a higher bid.
• Given the acquisition framework, further upside for Sage Therapeutics shares beyond the Supernus offer, including the CVRs, appears limited, positioning the stock primarily as an M&A arbitrage opportunity with a contingent value component.
• Investors in Supernus Pharmaceuticals should monitor the successful integration of Sage, the timely realization of the stated $200 million in annual cost synergies, and the commercial trajectory of Zurzuvae, as these are critical factors for the acquisition's value accretion.